Important Notice for TransMedics Group, Inc. (TMDX) Shareholders
New York, April 3, 2025 – The Gross Law Firm, a leading securities law firm, issues the following notice to all shareholders of TransMedics Group, Inc. (NASDAQ: TMDX):
Recently, The Gross Law Firm has received inquiries from concerned shareholders regarding potential securities law violations by TransMedics Group, Inc. As a result, our firm is investigating whether TransMedics and certain of its officers and directors have violated the federal securities laws.
Background
TransMedics is a medical technology company that specializes in organ preservation and transplantation technologies. The company’s flagship product is the Organ Care System (OCS), which is designed to keep donor organs viable outside the body until they can be transplanted. TransMedics’ stock price has seen significant volatility over the past year, with shares reaching an all-time high in February 2025 before experiencing a sharp decline in March.
Investigation Details
Our investigation focuses on whether TransMedics and certain of its executives made false and misleading statements to the market and investors regarding the commercial success and regulatory status of the OCS. Specifically, our firm is examining whether the company’s public statements regarding the regulatory approval process for the OCS were accurate and complete.
Implications for Shareholders
If it is determined that TransMedics and its executives have violated securities laws, shareholders may be able to recover their losses through a class action lawsuit. The Gross Law Firm encourages shareholders who purchased TMDX stock between January 1, 2023, and March 31, 2025, to contact the firm for a free consultation.
Impact on the World
The potential securities law violations at TransMedics could have far-reaching consequences beyond the company and its shareholders. If it is found that TransMedics made false or misleading statements regarding the OCS, it could undermine public trust in the medical technology industry and the regulatory approval process for new medical technologies.
Conclusion
The Gross Law Firm is committed to protecting the rights of investors and ensuring that companies comply with securities laws. Our investigation into TransMedics Group, Inc. is ongoing, and we encourage shareholders with questions or concerns to contact us for a free consultation. We will provide updates on the investigation as more information becomes available.
- The Gross Law Firm is investigating potential securities law violations by TransMedics Group, Inc.
- The investigation focuses on whether TransMedics and certain executives made false and misleading statements regarding the commercial success and regulatory status of the Organ Care System.
- Shareholders who purchased TMDX stock between January 1, 2023, and March 31, 2025, may be able to recover their losses through a class action lawsuit.
- The potential securities law violations could have far-reaching consequences, including undermining public trust in the medical technology industry and regulatory approval process.
